A Phase 1 Study of BH-30236 in People With Acute Myelogenous Leukemia or Higher-Risk Myelodysplastic Syndrome

Full Title

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Purpose

Researchers want to find the best dose of BH-30236 to treat people with leukemia. This study includes people with acute myelogenous leukemia (AML) that relapsed (came back) after treatment. It also includes people with higher-risk myelodysplastic syndrome (MDS). Higher-risk means a disease has a higher chance of coming back or not responding to standard treatment.

BH-30236 blocks proteins called CLK that may be abnormal in cancer cells. CLK proteins are important for controlling cell growth and survival. By blocking these proteins, BH-30236 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.